in the absence of a submission from the holder of the marketing authorisation:
chenodeoxycholic acid (Chenodeoxycholic acid Leadiant®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice355KB (PDF)
- Medicine name:
- chenodeoxycholic acid (Chenodeoxycholic acid Leadiant)
- SMC ID:
- The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.
- Pharmaceutical company
- Leadiant Biosciences
- BNF chapter
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 13 May 2019